---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Heterogeneity of treatment effect"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Heterogeneity of treatment effect. Topics: Company-presented survival by onset category and baseline miglustat use, Company-presented survival by baseline disease burden in infantile-onset disease, Company-presented disease progression by time from neurological onset to treatment, Neurological onset at 6 years or older: outside the approved indication, and 3 further topics. 7 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### Company-presented survival by onset category and baseline miglustat use

> “The OS benefit was seen in participants treated with miglustat and not treated with miglustat at baseline”
> “Survival benefit was consistent for early and late I-NPC, as well as for comparisons to each individual external control cohort”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

<a id="topic-2.2.2.3-2"></a>

### Company-presented survival by baseline disease burden in infantile-onset disease

> “No deaths were observed among 29 adrabetadex-treated participants with minimal baseline disease burden (R4DNPCCSS <4) during up to 11.3 years of treatment, consistent with earlier intervention before irreversible neurodegeneration.”
> “The median KM-estimated overall survival was numerically higher for adrabetadex-treated participants than for the untreated cohort in all the quartiles; in the severe quartile, the 5-year KM-estimated survival was 50% compared to 17%.”
> “Some caution is warranted when interpreting results between the two cohorts, considering the variations in group size, as well as the absence of a matching procedure between the two cohorts.”

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

<a id="topic-2.2.2.3-3"></a>

### Company-presented disease progression by time from neurological onset to treatment

> “A total of 25 participants were included (prompt treatment: n=9; delayed treatment: n=16) (Table 1).”
> “Median (Q1, Q3) baseline R4DNPCCSS score was lower in the prompt treatment group vs the delayed treatment group: 1.5 (0.50, 2.5) vs 5.0 (2.0, 10.0).”
> “Participants who initiated adrabetadex within 1 year of neurological symptom onset demonstrated numerically lower R4DNPCCSS progression from baseline scores compared with later treatment initiation.”

Source: [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)

<a id="topic-2.2.2.3-4"></a>

### Neurological onset at 6 years or older: outside the approved indication

> “Our work for families whose neurological symptoms began at age 6 or later continues, and we will keep you informed along the way.”

Source: [Beren Therapeutics LEMBAZ approval community update (2026)](https://www.berentx.com/news/community-update-lembaz-adrabetadex-is-approved/)

> “Review data from individuals with neurological onset at greater than 6 years of age”

Source: [Beren Therapeutics webinar community update (2026)](https://www.berentx.com/news/npc-webinar-highlights-path-forward-february-2026/)

<a id="topic-2.2.2.3-5"></a>

### Background miglustat or leucine use and the intravenous HPβCD treatment effect in TransportNPC

> “Prespecified analysis: Among patients receiving background miglustat and/or leucine therapy (n=78), Trappsol® Cyclo™ indicating slowing of disease progression by 71% compared with placebo at Week 96 (LS mean change from baseline of 0.46 vs 1.57 points; difference −1.11 points [95% CI −2.19, −0.02]; p=0.046).”

Source: [Rafael Holdings TransportNPC topline results release (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026104876/ea030712501ex99-1.htm)

<a id="topic-2.2.2.3-6"></a>

### Subtype differences for the other approved therapies: state Medicaid drug class review

> “There is insufficient evidence arimoclomol with miglustat is effective for adolescent- or adult-onset NPC.”
> “It is unclear if there are differences in efficacy and safety of either drug for other subtypes of NPC based on age of onset or specific mutation.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

<a id="topic-2.2.2.3-7"></a>

### Guideline statements on predicting treatment response by subtype

> “Additionally, predicting patient treatment responses remains challenging, further supporting the potential benefits of a combined therapeutic approach”
> “Future research priorities must focus on identifying the optimal timing for individual therapies during disease progression and understanding the most effective treatment combinations for various NPC patient subtypes.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
